1. Does 24-h Activity Cycle Influence Plasma PCSK9 Concentration? A Systematic Review and Meta-Analysis

   • Wan-chin Kuo
   • Jennifer M. Stevens
   • Lisa C. Bratzke

   Nonstatin Drugs ( M. Vrablik, Section Editor) 07 July 2020 Article: 30

   

2. Management of Structural Heart Disease and Acute Coronary Syndromes in the COVID-19 Pandemic

   • Arturo Giordano
   • Giuseppe Biondi-Zoccai
   • Antonio L. Bartorelli

   Commentary 10 June 2020 Article: 29

   

3. Periodontal Inflammation and the Risk of Cardiovascular Disease

   • Aditi Priyamvara
   • Amit K. Dey
   • Carl J. Lavie

   Coronary Heart Disease (S. Virani and S. Naderi, Section Editor) 08 June 2020 Article: 28

   

4. Statin Intolerance in Clinical Practice

   • Michaela Snejdrlova
   • T. Altschmiedova
   • R. Ceska

   Statin Drugs (R. Ceska, Section Editor) 03 June 2020 Article: 27

   

5. Clinical Pharmacology of Statins: an Update

   • Nicola Ferri
   • Alberto Corsini

   Statin Drugs (R. Ceska, Section Editor) 03 June 2020 Article: 26

   

6. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions

   • Aliza Hussain
   • Christie M. Ballantyne
   • Salim S Virani

   Coronary Heart Disease (S. Virani and S. Naderi, Section Editor) 03 June 2020 Article: 25

7. New Pharmacological Approaches to Target PCSK9

   • Alberico L. Catapano
   • Angela Pirillo
   • Giuseppe D. Norata

   Nonstatin Drugs (M. Vrablik, Section Editor) 03 June 2020 Article: 24